


This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 10-14 are added as follows:

10. (NEW) A therapeutic composition comprising 0.5 mg to 750 mg of a drug of the formula:




wherein the dotted line represents an unsaturation or a cycloalkenyl group; R<sub>1</sub> is a member selected from the group consisting of hydrogen and alkyl of 1 to 6 carbon atoms; R<sub>2</sub> is a member selected from the group consisting of hydrogen and alkyl of 1 to 6 carbon atoms; R<sub>4</sub> is a member selected from the group consisting of hydrogen, alkyl of 1 to 6 carbon atoms, formyl, and alkanoyl of 2 to 7 carbon atoms; R<sub>5</sub> and R<sub>6</sub> are independently a member selected from the group consisting of hydrogen, hydroxyl, an alkyl of 1 to 6 carbon atoms, an alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 7 carbon atoms, nitro, alkylmercapto of 1 to 6 carbon atoms, amino, alkylamino of 1 to 6 carbon atoms in which each alkyl group comprises 1 to 6 carbon atoms, alkanamide of 2 to 7 carbon atoms, halo and trifluoroethyl; R<sub>7</sub> is a member selected from the group consisting of hydrogen and alkyl of 1 to 6 carbons; and n is one of the integers 0, 1, 2, 3, 4, and a pharmaceutically acceptable addition salt; and wherein the drug of the formula is blended with a cellulose polymer.

USSN: 10/696,370, filed 10/28/2003  
AR02184USACON1  
Amendment / Reply to OA dated 11/12/2004


Page 2 of 6

11. (NEW) A therapeutic composition comprising 0.5 mg to 750 mg of a drug of the formula:



wherein the dotted line represents an unsaturation or a cycloalkenyl group; R<sub>1</sub> is a member selected from the group consisting of hydrogen and alkyl of 1 to 6 carbon atoms; R<sub>2</sub> is a member selected from the group consisting of hydrogen and alkyl of 1 to 6 carbon atoms; R<sub>4</sub> is a member selected from the group consisting of hydrogen, alkyl of 1 to 6 carbon atoms, formyl, and alkanoyl of 2 to 7 carbon atoms; R<sub>5</sub> and R<sub>6</sub> are independently a member selected from the group consisting of hydrogen, hydroxyl, an alkyl of 1 to 6 carbon atoms, an alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 7 carbon atoms, nitro, alkylmercapto of 1 to 6 carbon atoms, amino, alkylamino of 1 to 6 carbon atoms in which each alkyl group comprises 1 to 6 carbon atoms, alkanamide of 2 to 7 carbon atoms, halo and trifluoroethyl; R<sub>7</sub> is a member selected from the group consisting of hydrogen and alkyl of 1 to 6 carbons; and n is one of the integers 0, 1, 2, 3, and 4, and a pharmaceutically acceptable addition salt; and wherein the drug of the formula is blended with a maltodextrin polymer.

12. (New) A method for administering a drug to an environment of use, wherein the dosage form comprises a drug of the formula:



which dosage form comprises a member selected from the group consisting of a sustained-release dosage form and a controlled release dosage form, and wherein said dosage form and a controlled release dosage form, and wherein said dosage form comprises means for storing the drug and means for releasing the drug over an extended period of time.

13. (NEW) The therapeutic composition of claim 1, 10 or 11 or the dosage form of claim 8 or 12 in which the drug is chosen from the group consisting of venlafaxine and its pharmaceutically acceptable salts.

14. (NEW) The therapeutic composition of claim 1, 10 or 11 or the dosage form of claim 8 or 12 wherein the drug is venlafaxine hydrochloride.